Nurix Therapeutics
NRIX
About: Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.
Employees: 286
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
895% more call options, than puts
Call options by funds: $1.72M | Put options by funds: $173K
60% more repeat investments, than reductions
Existing positions increased: 69 | Existing positions reduced: 43
4.37% more ownership
Funds ownership: 111.48% [Q1] → 115.85% (+4.37%) [Q2]
0% more capital invested
Capital invested by funds: $1.01B [Q1] → $1.01B (+$819K) [Q2]
4% less funds holding
Funds holding: 170 [Q1] → 163 (-7) [Q2]
23% less first-time investments, than exits
New positions opened: 23 | Existing positions closed: 30
50% less funds holding in top 10
Funds holding in top 10: 2 [Q1] → 1 (-1) [Q2]
Research analyst outlook
5 Wall Street Analysts provided 1 year price targets over the past 3 months
5 analyst ratings
|
Oppenheimer
Matthew Biegler
|
$30
|
Outperform
Reiterated
|
31 Jul 2025 |
|
Morgan Stanley
Terence Flynn
|
$16
|
Equal-Weight
Maintained
|
15 Jul 2025 |
|
HC Wainwright & Co.
Robert Burns
|
$34
|
Buy
Maintained
|
14 Jul 2025 |
|
UBS
David Dai
|
$26
|
Buy
Maintained
|
10 Jul 2025 |
|
Stephens & Co.
Sudan Loganathan
|
$30
|
Overweight
Reiterated
|
10 Jul 2025 |
Financial journalist opinion
Based on 5 articles about NRIX published over the past 30 days
